AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01146873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine (D4T)
Description: Children are assigned to stay on their current antiretroviral regimen which includes D4T.
Study NCT01146873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Description: Children stop taking D4T and switch to ABC.
Study NCT01068028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741
Description: Ascending multiple doses to sequential panels
Study NCT01068028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ORM-12741
Study NCT02414386 — intervention group
Intervention type: OTHER
Intervention: biospecimen retention
Description: biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
Study NCT00945776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly phone calls
Description: Calling weekly to answer questions regarding CPAP usage.
Study NCT00945776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Frequently asked questions
Description: Answers to frequently asked questions in pre-printed form.
Study NCT00945776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
Study NCT00404014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL-208
Description: 1 dose of 300 mg
Study NCT00404014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose of placebo
Study NCT01650636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)
Description: Ten (10) 90-min sessions of Health Information delivered via videophones
Study NCT01650636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)
Description: Ten (10) 90-min sessions of T-PP-CBSM
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil)
Description: 4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 (cholecalciferol) placebo
Description: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) placebo
Description: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid placebo
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
Study NCT03313076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acid placebo
Description: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
Study NCT02550886 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
Study NCT02192827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate Injection
Study NCT02335827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irreversible electroporation
Description: Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
Study NCT02261727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
Study NCT02261727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
Study NCT02261727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for prednisone)
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily
Study NCT02261727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for prednisone)
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily
Study NCT02261727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Theophylline)
Description: One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
Study NCT02329769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC 6 mg/kg
Study NCT02329769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV 6 mg/kg
Study NCT02329769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV 9 mg/kg
Study NCT05506189 — intervention group
Intervention type: OTHER
Intervention: mobile application program with human coach
Description: 6-months mobile application program with human coach for life-style modifiation including diet and exercise
Study NCT03269123 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pressop 1
Description: A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
Study NCT03923569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Overnight polysomnography
Description: Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
Study NCT03923569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: blood sample for genetic testing of the Apolipoprotein E
Study NCT03923569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: high-resolution MRI scan
Description: Evaluation of anomalies in brain structure and functional resting state connectivity
Study NCT03923569 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: neuropsychological evaluation including episodic memory tests before an overnight polysomnography
Study NCT02636088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT03267121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: 500 mg qd.p.o. every day for 21 days as a cycle
Study NCT03267121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur Gimeracil Oteracil Potassium Capsules
Description: 25mg/㎡ bid p.o. every day for 14 days as a cycle
Study NCT01974544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
Study NCT01974544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass
Description: For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
Study NCT01974544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
Study NCT01974544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General interventions for all groups: blood presure
Description: Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
Study NCT01974544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General interventions for all groups: dysilipidemia
Description: Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration >4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (>4.0 mmol/L).
Study NCT01974544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General interventions for all groups: lifestyle
Description: Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
Study NCT04778254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK attachment retained obturator
Description: attachment retained obturator for management of hemi maxillectomy
Study NCT04778254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metalic attachment retained obturator
Description: attachment retained obturator for management of hemi maxillectomy
Study NCT04778254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional obturator
Description: clasp retained obturator for management of hemi maxillectomy
Study NCT01018498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted FODMAPs diet
Description: Restricted fermentable substrate diet
Study NCT01453855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.003%
Study NCT01453855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost ophthalmic solution, 0.004%
Study NCT02567890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based DBI
Description: Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
Study NCT02567890 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Participants will be asked to reflect upon issues related to body image.
Study NCT03699007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exposure Therapy (GET Living)
Description: The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
Study NCT03699007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary Pain Management (MPM)
Description: The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
Study NCT01751308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Injection Route of administration: Intravenous
Study NCT02127437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: 120 mg, subcutaneously, once every 4 weeks
Study NCT02127437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0,5 ml, subcutaneously, once every 4 weeks
Study NCT03046875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
Study NCT03046875 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
Study NCT03001674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conductance catheterization
Description: CD Leycom Conductance Catheter
Study NCT01554137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isokinetic strength training
Description: The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
Study NCT01554137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: passive motion
Description: The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
Study NCT01263639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopaedic Attending Biosketch Card
Description: The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
Study NCT01263639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care - No biosketch card
Description: Standard of care
Study NCT02981875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oculomotor training
Description: a sequence of vision training exercises which focused mainly in oculomotor skill
Study NCT02981875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo vision training exercises involving minimal accommodation and vergence eye movement.
Study NCT00252057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Engineered Hospital Discharge
Description: The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist.
Study NCT04646759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant combined with Pyrotinib
Description: Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
Study NCT04646759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine combined with Pyrotinib
Description: Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
Study NCT03129659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography
Description: Coronary CT angiography
Study NCT02010164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Co-enzyme Q10
Description: 600mg for 3 months
Study NCT03594188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthetic methods
Description: Patients will receive standard GA or LA for RF surgery.
Study NCT03594188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anesthetic methods
Description: Patients will receive standard GA or LA for RF surgery.
Study NCT03668483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
Study NCT05477290 — intervention group
Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Transverse Incision
Description: At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
Study NCT05477290 — intervention group
Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Oblique Incision
Description: At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
Study NCT05477290 — intervention group
Intervention type: PROCEDURE
Intervention: Trigger Finger Release through Vertical Incision
Description: At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
Study NCT00832507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
Study NCT00832507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cicletanine
Description: Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
Study NCT00832507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cicletanine Placebo
Description: Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
Study NCT04971304 — intervention group
Intervention type: DRUG
Intervention: Receipt of granulocyte-colony stimulating factor
Description: Receipt of originator or biosimilar
Study NCT03326843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Description: Oral avatrombopag administered once daily for 5 days prior to procedure.
Study NCT00657891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
Study NCT00657891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection
Study NCT00705783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole depot
Description: Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Study NCT00705783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo depot
Description: Placebo depot was supplied in 400 mg lyophilized vials.